Screening Adolescents for GLP-1 Therapy Candidacy
Placeholder: age, pediatric BMI percentile, and comorbidity criteria reviewed.
- 12 yrs: Minimum age (Placeholder eligibility floor)
- ≥95th pct: BMI threshold (Placeholder age/sex-adjusted)
- Required: Comorbidity screen (Placeholder pre-therapy workup)
- Pediatric endo: Specialist referral (Placeholder care team)
Eligibility criteria overview
Placeholder: age and BMI percentile define candidacy, not adult BMI cutoffs.
Baseline health assessment
Placeholder: labs, growth history, and pubertal stage recorded before start.
Placeholder highlight: pediatric criteria differ meaningfully from adult thresholds.
Age-Adjusted Titration Distinct From Adult Protocols
Placeholder: dosing scales to body weight with a slower titration curve.
- Slower: Titration pace (Placeholder vs. adult schedule)
- mg/kg: Dosing basis (Placeholder weight-adjusted)
- Low: Starting dose (Placeholder conservative start)
- 4 weeks: Titration interval (Placeholder step-up cadence)
Weight-based dose calculation
Placeholder: dose scaled per kilogram, reassessed as weight changes.
Titration safety checkpoints
Placeholder: GI tolerability reviewed before each dose increase step.
Placeholder highlight: slower titration reduces adverse event frequency in teens.
Tracking Height Velocity and Pubertal Staging During Therapy
Placeholder: growth curves monitored alongside weight to catch deviations early.
- Every visit: Height check (Placeholder monitoring cadence)
- Tracked: Tanner staging (Placeholder pubertal assessment)
- CDC/WHO: Growth chart (Placeholder percentile reference)
- Velocity drop: Alert trigger (Placeholder safety flag)
Height velocity tracking
Placeholder: growth trajectory plotted against normative percentile bands.
Pubertal stage correlation
Placeholder: Tanner stage checked to contextualize expected growth pace.
Placeholder highlight: sustained growth deceleration prompts dose review.
Body Image, Family Support, and Peer Environment in Teens
Placeholder: adolescent-specific psychosocial factors shape therapy outcomes.
- Included: Body image screen (Placeholder assessment tool)
- Recommended: Family sessions (Placeholder involvement plan)
- Reviewed: School environment (Placeholder peer context)
- 0–100: Support score range (Placeholder composite metric)
Family-centered counseling
Placeholder: caregivers included in goal-setting and follow-up visits.
Peer and school context
Placeholder: school stigma and peer dynamics factored into care plan.
Placeholder highlight: higher family support correlates with better adherence.
Safety Profile Comparable to Adults, With Closer Pediatric Oversight
Placeholder: trial data shows adult-similar safety with added monitoring needs.
- Similar: Adverse event rate (Placeholder vs. adult trials)
- Closer: Growth monitoring (Placeholder pediatric requirement)
- Family-centered: Care model (Placeholder follow-up approach)
- Limited: Long-term data (Placeholder ongoing research need)
Trial safety summary
Placeholder: GI effects most common, consistent with adult safety data.
Long-term follow-up needs
Placeholder: growth, puberty, and psychosocial status reassessed periodically.
Placeholder highlight: family-centered follow-up remains central to pediatric safety.